Operational plan for comprehensive HIV and AIDS care and ...

More documents

Recommendations

Info

DRAFT - Confidential Figure 1.1: Entry into Continuum of Care HIV Testing, Counseling and Clinical Staging VCT/PMTCT/Testing Access Prevention counseling Patient information capture HIV test Negative Positive Prevention counseling Prevention counseling Services introduction Staging Laboratory (CD4) Clinical Negative TB Screening Positive Start Prophylaxis Referral to TB Clinic A) Adult < 200 Symptomatic B) Adult 200-500 Asymptomatic C) Adult 500+ Asymptomatic D) Paediatric
DRAFT - Confidential practitioners, hospice, and palliative care provided by a full range of NGOs, CBOs, FBOs, and support groups run by persons living with HIV and AIDS (Figure 1.2). Figure 1.2: Continuum of Care Services Care and Treatment Services Services Coordination and Management HIV Testing Access Point Medical Treatment & Drug Therapy Clinical & Laboratory Monitoring Adherence Support Community & Home- Based Care Ancillary Support Services, e.g. CBOs, FBOs, THPs 3. Referral and Consultation For patients with complex medical needs related to HIV, it is necessary that consultation and referral mechanisms are available to ensure that appropriate patient care is delivered. Clinicians from district hospitals will initiate most requests for consultation and patient referrals. Such requests will be channelled to the appropriate district or regional hospital, following a preliminary clinical assessment. Consultative capability in the referral hospital should include: Infectious Disease Control, Internal Medicine, Neurology, Ophthalmology, Gastroenterology, Oncology and Paediatrics. When the specialist is located in a different facility, issues around transportation and follow-up need to be formalised to ensure that the recommendations by the referring clinician are carried out. The patient should be referred back to the original referring provider for continuity of medical care wherever possible. - 4. Home-Based Care NGOs and CBOs can provide care services in the home. Home-based care is a particularly useful tool to assess and support patient adherence to ARV and other therapies, including locating and reaching out to patients who miss scheduled appointments, promoting continuity of care and adherence with ARV regimens. Palliative care services can also be provided through home-based programmes working to train and support the patients’ families and friends to ensure the highest achievable quality of life. Chapter I: Prevention, Care and Treatment 58
Page 1 and 2:
OPERATIONAL PLAN FOR COMPREHENSIVE
Page 3 and 4:
LIST OF TABLES Table 0.1: Total Pro
Page 5 and 6:
LIST OF ACRONYMS ADR AIDS ALT API A
Page 7 and 8: Foreword I would like to thank the
Page 9 and 10: We hope that all South Africans who
Page 11 and 12: 16. Dr. Fazel Randera, Health Advis
Page 13 and 14: Executive Summary BACKGROUND 1. The
Page 15 and 16: 6. Following the discussion of this
Page 17 and 18: health status and to prolong life),
Page 19 and 20: extreme inequalities and disparitie
Page 21 and 22: 9.5 Providing a Comprehensive Conti
Page 23 and 24: efforts through additional investme
Page 25 and 26: elements in a containment strategy
Page 27 and 28: 18. The programme detailed in this
Page 29 and 30: monitoring of patients for TB, a co
Page 31 and 32: 40 The drug procurement strategies
Page 33 and 34: follow-up and monitoring for patien
Page 35 and 36: CHAPTER III - TRADITIONAL MEDICINE
Page 37 and 38: 74 The minimum service point accred
Page 39 and 40: 85. Task Team projections of AIDS p
Page 41 and 42: patented and/or branded drugs suppl
Page 43 and 44: 102. It proposes a significant expa
Page 45 and 46: measure the outcomes of the program
Page 47 and 48: 119. Examples of specific research
Page 49 and 50: Table 0.1: Total Programme Budget E
Page 51 and 52: the existing health care system and
Page 53 and 54: Table 0.2: New Patients Starting AR
Page 55 and 56: DRAFT - Confidential Chapter I Prev
Page 57: DRAFT - Confidential The key preven
Page 61 and 62: DRAFT - Confidential 6. Levels of C
Page 63 and 64: DRAFT - Confidential Patients seen
Page 65 and 66: DRAFT - Confidential c. Adult ARV D
Page 67 and 68: DRAFT - Confidential increased freq
Page 69 and 70: DRAFT - Confidential first few week
Page 71 and 72: DRAFT - Confidential development of
Page 73 and 74: DRAFT - Confidential evidence, nevi
Page 75 and 76: DRAFT - Confidential their lives. A
Page 77 and 78: DRAFT - Confidential point of conta
Page 79 and 80: DRAFT - Confidential ADMINISTRATIVE
Page 81 and 82: DRAFT - Confidential joint collabor
Page 83 and 84: DRAFT - Confidential reduces the po
Page 85 and 86: DRAFT - Confidential Coordination w
Page 87 and 88: DRAFT - Confidential Chapter III Tr
Page 89 and 90: DRAFT - Confidential In addition to
Page 91 and 92: DRAFT - Confidential Development of
Page 93 and 94: DRAFT - Confidential SPECIAL CONSID
Page 95 and 96: DRAFT - Confidential SECTION TWO HU
Page 97 and 98: DRAFT - Confidential collaboration
Page 99 and 100: DRAFT - Confidential effectiveness)
Page 101 and 102: DRAFT - Confidential 18. A system i
Page 103 and 104: DRAFT - Confidential Chapter V Huma
Page 105 and 106: DRAFT - Confidential • ARV treatm
Page 107 and 108: DRAFT - Confidential Table 5.3: Cor
Page 109 and 110:
DRAFT - Confidential Table 5.5: Tot
Page 111 and 112:
DRAFT - Confidential forward, the e
Page 113 and 114:
DRAFT - Confidential The general ch
Page 115 and 116:
DRAFT - Confidential • ARV treatm
Page 117 and 118:
DRAFT - Confidential Human Resource
Page 119 and 120:
DRAFT - Confidential met. These bur
Page 121 and 122:
DRAFT - Confidential capacity in ma
Page 123 and 124:
DRAFT - Confidential will be streng
Page 125 and 126:
DRAFT - Confidential 4. Explore cha
Page 127 and 128:
DRAFT - Confidential ADMINISTRATIVE
Page 129 and 130:
DRAFT - Confidential Chapter VI PRO
Page 131 and 132:
DRAFT - Confidential Table 6.3 list
Page 133 and 134:
DRAFT - Confidential Laboratories N
Page 135 and 136:
DRAFT - Confidential Table 6.1: Fac
Page 137 and 138:
DRAFT - Confidential Table 6.2: Pro
Page 139 and 140:
DRAFT - Confidential prevalences, t
Page 141 and 142:
DRAFT - Confidential Table 6.3: Sit
Page 143 and 144:
DRAFT - Confidential SECTION THREE
Page 145 and 146:
DRAFT - Confidential generic produc
Page 147 and 148:
DRAFT - Confidential Fourthly, the
Page 149 and 150:
DRAFT - Confidential Security of Su
Page 151 and 152:
DRAFT - Confidential SPECIAL CONSID
Page 153 and 154:
DRAFT - Confidential manufacturer.
Page 155 and 156:
DRAFT - Confidential • Management
Page 157 and 158:
DRAFT - Confidential delivery, the
Page 159 and 160:
DRAFT - Confidential Pharmacies at
Page 161 and 162:
DRAFT - Confidential • The Pharma
Page 163 and 164:
DRAFT - Confidential as a contingen
Page 165 and 166:
DRAFT - Confidential the first five
Page 167 and 168:
DRAFT - Confidential • Improving
Page 169 and 170:
DRAFT - Confidential Johannesburg.
Page 171 and 172:
DRAFT - Confidential Infant diagnos
Page 173 and 174:
DRAFT - Confidential SECTION FOUR C
Page 175 and 176:
DRAFT - Confidential Chapter X Soci
Page 177 and 178:
DRAFT - Confidential • Clear guid
Page 179 and 180:
DRAFT - Confidential communities, a
Page 181 and 182:
DRAFT - Confidential Care and Suppo
Page 183 and 184:
DRAFT - Confidential The communicat
Page 185 and 186:
DRAFT - Confidential SECTION FIVE I
Page 187 and 188:
DRAFT - Confidential The systems sh
Page 189 and 190:
DRAFT - Confidential and location o
Page 191 and 192:
DRAFT - Confidential should enable
Page 193 and 194:
DRAFT - Confidential The Cluster of
Page 195 and 196:
DRAFT - Confidential or services. O
Page 197 and 198:
DRAFT - Confidential Monitoring of
Page 199 and 200:
DRAFT - Confidential The majority o
Page 201 and 202:
DRAFT - Confidential Comparable rol
Page 203 and 204:
DRAFT - Confidential Chapter XIII P
Page 205 and 206:
DRAFT - Confidential drug-food inte
Page 207 and 208:
DRAFT - Confidential Antimicrobial
Page 209 and 210:
DRAFT - Confidential PROGRAMME ASSE
Page 211 and 212:
DRAFT - Confidential agenda: to con
Page 213 and 214:
DRAFT - Confidential South African
Page 215 and 216:
DRAFT - Confidential AIDS in South
Page 217 and 218:
DRAFT - Confidential There has been
Page 219 and 220:
DRAFT - Confidential • What is th
Page 221 and 222:
DRAFT - Confidential HIV infection
Page 223 and 224:
DRAFT - Confidential • Determinat
Page 225 and 226:
DRAFT - Confidential Research Overs
Page 227 and 228:
DRAFT - Confidential SECTION SIX MA
Page 229 and 230:
DRAFT - Confidential continual revi
Page 231 and 232:
DRAFT - Confidential The work of th
Page 233 and 234:
DRAFT - Confidential Figure 15.3: C
Page 235 and 236:
DRAFT - Confidential continuous pro
Page 237 and 238:
DRAFT - Confidential Finally, mecha
Page 239 and 240:
DRAFT - Confidential protocols. The
Page 241 and 242:
DRAFT - Confidential Table 16.1: Es
Page 243 and 244:
DRAFT - Confidential required for t
Page 245 and 246:
DRAFT - Confidential and consumable
Page 247 and 248:
DRAFT - Confidential will also allo
Page 249 and 250:
DRAFT - Confidential Table 16.8: Pl
Page 251 and 252:
DRAFT - Confidential Table 16.11: T
Page 253 and 254:
DRAFT - Confidential mechanisms to
Page 255 and 256:
DRAFT - Confidential Table 16.16: S
Page 257 and 258:
DRAFT - Confidential Table 16.19: T
Page 259 and 260:
DRAFT - Confidential Given the cons
Page 261 and 262:
DRAFT - Confidential month follow-u
show all

Operational plan for comprehensive HIV and AIDS care and ...

Create successful ePaper yourself

Delete template?

Save as template?